FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088596048> ?p ?o ?g. }

• W3088596048 endingPage "S813" @default.
• W3088596048 startingPage "S813" @default.
• W3088596048 abstract "In preclinical studies, the combination of amivantamab (EGFR-MET bispecific antibody) with lazertinib demonstrates synergistic inhibition of tumor growth. We present the safety and early efficacy results of patients receiving amivantamab in combination with lazertinib in the phase 1 CHRYSALIS study (NCT02609776). Patients with EGFR Exon 19 deletion or L858R mutation non-small cell lung cancer (NSCLC) were enrolled in this 2-part study. To identify the recommended phase 2 combination dose (RP2CD), Part 1 enrolled patients without restriction on prior therapy to evaluate escalating dose cohorts of amivantamab (700–1050 mg, iv once weekly for 28 days; biweekly thereafter) in combination with standard monotherapy dosing of lazertinib (240 mg oral daily). The ongoing Part 2 dose expansion Cohort E is evaluating preliminary efficacy, without biomarker selection, in patients progressing on osimertinib. Response was assessed by investigator per RECIST v1.1. As of 17 March 2020, 71 patients received the combination: median age was 61 y (36–79), median prior lines was 1 (0–9). In Part 1, the RP2CD was the maximally assessed doses of 1050 mg (1400 mg, ≥80 kg) amivantamab + 240 mg lazertinib. Interim safety profile includes rash (78%), infusion related reaction (61%), paronychia (42%), stomatitis (31%), pruritus (24%), and diarrhea (14%). Majority of treatment-related AEs were grade 1–2, with grade ≥3 reported in 7%. As of 30 April 2020, in 23 Part 1 patients with measurable disease, the overall response rate (ORR) was 43.5% (95% CI, 23.2–65.5) with 10 partial responses (PRs), and 9 patients with stable disease (SD); median treatment duration was 8.2 months (0.5–10.7), with 13 patients still ongoing. In the post-osimertinib expansion Cohort E, early antitumor activity is being observed in 14/20 response-evaluable patients with 1 complete response, 7 PRs (2 pending confirmation), and 6 SD with tumor shrinkage. Amivantamab can be combined safely with lazertinib at their respective full monotherapy doses. Encouraging preliminary activity was observed in osimertinib-relapsed disease: updated data will be presented." @default.
• W3088596048 created "2020-10-01" @default.
• W3088596048 creator A5005462156 @default.
• W3088596048 creator A5006869052 @default.
• W3088596048 creator A5012122212 @default.
• W3088596048 creator A5013149755 @default.
• W3088596048 creator A5014695760 @default.
• W3088596048 creator A5024203424 @default.
• W3088596048 creator A5028976895 @default.
• W3088596048 creator A5034407359 @default.
• W3088596048 creator A5042316451 @default.
• W3088596048 creator A5043697255 @default.
• W3088596048 creator A5044613951 @default.
• W3088596048 creator A5054907647 @default.
• W3088596048 creator A5062034160 @default.
• W3088596048 creator A5064494204 @default.
• W3088596048 creator A5067727178 @default.
• W3088596048 creator A5080207463 @default.
• W3088596048 creator A5081591010 @default.
• W3088596048 creator A5082091984 @default.
• W3088596048 creator A5086102379 @default.
• W3088596048 creator A5087695265 @default.
• W3088596048 date "2020-09-01" @default.
• W3088596048 modified "2023-09-30" @default.
• W3088596048 title "1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC" @default.
• W3088596048 doi "https://doi.org/10.1016/j.annonc.2020.08.1572" @default.
• W3088596048 hasPublicationYear "2020" @default.
• W3088596048 type Work @default.
• W3088596048 sameAs 3088596048 @default.
• W3088596048 citedByCount "26" @default.
• W3088596048 countsByYear W30885960482020 @default.
• W3088596048 countsByYear W30885960482021 @default.
• W3088596048 countsByYear W30885960482022 @default.
• W3088596048 countsByYear W30885960482023 @default.
• W3088596048 crossrefType "journal-article" @default.
• W3088596048 hasAuthorship W3088596048A5005462156 @default.
• W3088596048 hasAuthorship W3088596048A5006869052 @default.
• W3088596048 hasAuthorship W3088596048A5012122212 @default.
• W3088596048 hasAuthorship W3088596048A5013149755 @default.
• W3088596048 hasAuthorship W3088596048A5014695760 @default.
• W3088596048 hasAuthorship W3088596048A5024203424 @default.
• W3088596048 hasAuthorship W3088596048A5028976895 @default.
• W3088596048 hasAuthorship W3088596048A5034407359 @default.
• W3088596048 hasAuthorship W3088596048A5042316451 @default.
• W3088596048 hasAuthorship W3088596048A5043697255 @default.
• W3088596048 hasAuthorship W3088596048A5044613951 @default.
• W3088596048 hasAuthorship W3088596048A5054907647 @default.
• W3088596048 hasAuthorship W3088596048A5062034160 @default.
• W3088596048 hasAuthorship W3088596048A5064494204 @default.
• W3088596048 hasAuthorship W3088596048A5067727178 @default.
• W3088596048 hasAuthorship W3088596048A5080207463 @default.
• W3088596048 hasAuthorship W3088596048A5081591010 @default.
• W3088596048 hasAuthorship W3088596048A5082091984 @default.
• W3088596048 hasAuthorship W3088596048A5086102379 @default.
• W3088596048 hasAuthorship W3088596048A5087695265 @default.
• W3088596048 hasBestOaLocation W30885960481 @default.
• W3088596048 hasConcept C121608353 @default.
• W3088596048 hasConcept C126322002 @default.
• W3088596048 hasConcept C143998085 @default.
• W3088596048 hasConcept C197934379 @default.
• W3088596048 hasConcept C2776256026 @default.
• W3088596048 hasConcept C2776694085 @default.
• W3088596048 hasConcept C2776999253 @default.
• W3088596048 hasConcept C2777930144 @default.
• W3088596048 hasConcept C2778570526 @default.
• W3088596048 hasConcept C2778822529 @default.
• W3088596048 hasConcept C2779177807 @default.
• W3088596048 hasConcept C2779438470 @default.
• W3088596048 hasConcept C2779984678 @default.
• W3088596048 hasConcept C2780580887 @default.
• W3088596048 hasConcept C2781413609 @default.
• W3088596048 hasConcept C535046627 @default.
• W3088596048 hasConcept C61943457 @default.
• W3088596048 hasConcept C71924100 @default.
• W3088596048 hasConcept C81729549 @default.
• W3088596048 hasConcept C90924648 @default.
• W3088596048 hasConceptScore W3088596048C121608353 @default.
• W3088596048 hasConceptScore W3088596048C126322002 @default.
• W3088596048 hasConceptScore W3088596048C143998085 @default.
• W3088596048 hasConceptScore W3088596048C197934379 @default.
• W3088596048 hasConceptScore W3088596048C2776256026 @default.
• W3088596048 hasConceptScore W3088596048C2776694085 @default.
• W3088596048 hasConceptScore W3088596048C2776999253 @default.
• W3088596048 hasConceptScore W3088596048C2777930144 @default.
• W3088596048 hasConceptScore W3088596048C2778570526 @default.
• W3088596048 hasConceptScore W3088596048C2778822529 @default.
• W3088596048 hasConceptScore W3088596048C2779177807 @default.
• W3088596048 hasConceptScore W3088596048C2779438470 @default.
• W3088596048 hasConceptScore W3088596048C2779984678 @default.
• W3088596048 hasConceptScore W3088596048C2780580887 @default.
• W3088596048 hasConceptScore W3088596048C2781413609 @default.
• W3088596048 hasConceptScore W3088596048C535046627 @default.
• W3088596048 hasConceptScore W3088596048C61943457 @default.
• W3088596048 hasConceptScore W3088596048C71924100 @default.
• W3088596048 hasConceptScore W3088596048C81729549 @default.
• W3088596048 hasConceptScore W3088596048C90924648 @default.
• W3088596048 hasLocation W30885960481 @default.
• W3088596048 hasOpenAccess W3088596048 @default.

• next